Literature DB >> 21077951

Hyponatremia a valuable predictor of early mortality in patients with cirrhosis listed for liver transplantation.

Maryam Moini1, Mohammad Kazem Hoseini-Asl, Seyed Alireza Taghavi, Mohammad M Sagheb, Saman Nikeghbalian, Heshmatalah Salahi, Ali Bahador, Motahareh Motazedian, Peyman Jafari, Sayed Ali Malek-Hosseini.   

Abstract

The current policy for organ allocation in liver transplantation is to give priority to the sickest patients mostly using model for end-stage liver disease (MELD) score in ranking. However, other factors as serum sodium may be of value in predicting early mortality. In this single-center study, patients with cirrhosis over age 14 on the liver transplant wait-list from September 1998 to June 2007 were followed for six months from the time of listing to evaluate the value of hyponatremia on mortality. Of 612 listed patients, 51 were transplanted who were excluded from survival analysis and 55 died without transplantation within the first three months. The numbers of transplanted and dead patients during months 3-6 were 29 and 24, respectively. Both MELD score and serum sodium at the time of listing were independent predictors of early mortality. On bivariate analysis, serum sodium of <130 mEq/L beside MELD was a significant predictor of mortality within 90 and 180 d. Serum sodium level <135 mEq/L masked the difference in mortality between patients with refractory and non-refractory ascites. Serum sodium level of <130 mEq/L and an increased MELD score are significant predictors of early mortality in patients listed for liver transplantation.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21077951     DOI: 10.1111/j.1399-0012.2010.01350.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  12 in total

Review 1.  Model for End-stage Liver Disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  J Clin Exp Hepatol       Date:  2012-12-01

Review 2.  Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise.

Authors:  G Liamis; T D Filippatos; A Liontos; M S Elisaf
Journal:  Hepatol Int       Date:  2016-06-21       Impact factor: 6.047

Review 3.  Advances in liver transplantation allocation systems.

Authors:  Michael L Schilsky; Maryam Moini
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

4.  Hyponatremia, mineral metabolism, and mortality in incident maintenance hemodialysis patients: a cohort study.

Authors:  Sagar U Nigwekar; Julia Wenger; Ravi Thadhani; Ishir Bhan
Journal:  Am J Kidney Dis       Date:  2013-04-13       Impact factor: 8.860

5.  MELD-sodium score and its prognostic value in malignancy-related ascites of pancreatic and gastric cancer.

Authors:  Hüseyin Engin; Cemil Bilir; Yücel Ustündağ
Journal:  Support Care Cancer       Date:  2012-10-27       Impact factor: 3.603

6.  Improving survival in decompensated cirrhosis.

Authors:  Amar Nath Mukerji; Vishal Patel; Ashokkumar Jain
Journal:  Int J Hepatol       Date:  2012-07-02

7.  Prognostic Significance of Ascites and Serum Sodium in Patients with Low Meld Scores.

Authors:  Dzanela Prohic; Rusmir Mesihovic; Nenad Vanis; Amra Puhalovic
Journal:  Med Arch       Date:  2016-01-31

8.  Implications of Hyponatremia in Liver Transplantation.

Authors:  Sertac Cimen; Sanem Guler; Subhashini Ayloo; Michele Molinari
Journal:  J Clin Med       Date:  2014-12-29       Impact factor: 4.241

9.  Evaluation of Adrenal Function in Nonhospitalized Patients with Cirrhosis.

Authors:  Maryam Moini; Mitra Yazdani Sarvestani; Mesbah Shams; Masood Nomovi
Journal:  Can J Gastroenterol Hepatol       Date:  2017-07-24

10.  Predictors of refractory ascites development in patients with hepatitis B virus-related cirrhosis hospitalized to control ascitic decompensation.

Authors:  Ju Hee Seo; Seung Up Kim; Jun Yong Park; Do Young Kim; Kwang-Hyub Han; Chae Yoon Chon; Sang Hoon Ahn
Journal:  Yonsei Med J       Date:  2013-01-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.